|
SI1523496T1
(sl)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Rekombinantno proizvajanje zmesi protiteles
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
PL2853545T3
(pl)
|
2008-09-17 |
2016-12-30 |
|
Przeciwciało swoiste wobec IgE
|
|
TWI646193B
(zh)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
抗體恆定區域改變體
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CA2781519A1
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
SMT201900372T1
(it)
|
2010-02-08 |
2019-09-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
CN110066339A
(zh)
|
2010-04-20 |
2019-07-30 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
|
EP2569337A1
(en)
*
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
|
TR201802772T4
(tr)
|
2010-11-17 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
HUE068728T2
(hu)
|
2011-08-05 |
2025-01-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
ES2971444T3
(es)
|
2011-10-11 |
2024-06-05 |
F Hoffmann Lar Roche Ag |
Ensamblaje mejorado de anticuerpos biespecíficos
|
|
SG11201401422VA
(en)
*
|
2011-10-27 |
2014-09-26 |
Genmab As |
Production of heterodimeric proteins
|
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
|
HK1201851A1
(en)
|
2011-11-11 |
2015-09-11 |
瑞纳神经科学公司 |
Antibodies specific for trop-2 and their uses
|
|
CN102558355B
(zh)
*
|
2011-12-31 |
2015-02-25 |
苏州康宁杰瑞生物科技有限公司 |
基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
ES2743399T3
(es)
*
|
2012-04-20 |
2020-02-19 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
|
IN2015DN01115A
(enExample)
|
2012-07-13 |
2015-06-26 |
Zymeworks Inc |
|
|
AU2013302696B9
(en)
*
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US10358492B2
(en)
*
|
2012-09-27 |
2019-07-23 |
Merus N.V. |
Bispecific IgG antibodies as T cell engagers
|
|
JP6581505B2
(ja)
|
2012-10-03 |
2019-09-25 |
ザイムワークス，インコーポレイテッド |
重鎖および軽鎖ポリペプチドの対を定量化する方法
|
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
DK2927321T3
(da)
|
2012-11-27 |
2021-03-15 |
Univ Ajou Ind Academic Coop Found |
Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf
|
|
KR102545617B1
(ko)
|
2012-11-28 |
2023-06-20 |
자임워크스 비씨 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR20200024345A
(ko)
|
2013-01-10 |
2020-03-06 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
WO2014131711A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
EA201891502A1
(ru)
|
2013-02-26 |
2018-12-28 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
KR101813708B1
(ko)
*
|
2013-03-13 |
2017-12-29 |
(주) 아이벤트러스 |
소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법
|
|
CN105358575B
(zh)
|
2013-03-15 |
2020-09-22 |
詹森生物科技公司 |
干扰素α和ω抗体拮抗剂
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
|
EP3587448B1
(en)
*
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR20160006168A
(ko)
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
TWI653243B
(zh)
|
2013-04-29 |
2019-03-11 |
赫孚孟拉羅股份公司 |
遏止ＦｃＲｎ結合之抗ＩＧＦ－１Ｒ抗體及其治療血管性眼疾之用途
|
|
KR102266819B1
(ko)
|
2013-04-29 |
2021-06-18 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
|
|
JP2016528167A
(ja)
|
2013-04-29 |
2016-09-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ヒトＦｃＲｎ結合改変抗体及び使用方法
|
|
CA2913370C
(en)
*
|
2013-05-31 |
2022-12-13 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
ME03675B
(me)
|
2013-07-05 |
2020-10-20 |
Genmab As |
Humanizovana ili himerna anтi-cd3 antiтela
|
|
WO2015015401A2
(en)
|
2013-08-02 |
2015-02-05 |
Pfizer Inc. |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
|
ES2881306T3
(es)
*
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
LT3065774T
(lt)
|
2013-11-06 |
2021-09-10 |
Janssen Biotech, Inc. |
Anti-ccl17 antikūnai
|
|
MX376384B
(es)
|
2013-11-27 |
2025-03-07 |
Zymeworks Bc Inc |
Construcciones de union a antigenos biespecificas dirigidas a her2.
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
KR102357961B1
(ko)
*
|
2013-12-17 |
2022-02-08 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
CA2932958A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
|
BR112016015589A2
(pt)
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
|
BR112016016416A2
(pt)
|
2014-01-15 |
2017-10-03 |
Hoffmann La Roche |
VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
|
|
SG11201607109QA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
SI3110849T1
(sl)
|
2014-02-28 |
2021-01-29 |
Merus N.V. |
Protitelo, ki veže ERBB-2 in ERBB-3
|
|
RU2016141307A
(ru)
|
2014-03-21 |
2018-04-24 |
Регенерон Фармасьютикалз, Инк. |
Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
EP3126389B1
(en)
|
2014-04-02 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Method for detecting multispecific antibody light chain mispairing
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
US11505605B2
(en)
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
EP3143043B1
(en)
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispecific antibodies with engineered ch1-cl interfaces
|
|
EA201692476A1
(ru)
|
2014-05-28 |
2017-07-31 |
Займворкс Инк. |
Модифицированные антигенсвязывающие полипептидные конструкции и их применение
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
WO2015197736A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
US20170218091A1
(en)
*
|
2014-07-03 |
2017-08-03 |
Abbvie Inc. |
Monovalent binding proteins
|
|
ES2774428T3
(es)
|
2014-07-11 |
2020-07-21 |
Genmab As |
Anticuerpos que se unen a AXL
|
|
KR102411972B1
(ko)
|
2014-08-04 |
2022-06-23 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
MY192918A
(en)
|
2014-09-09 |
2022-09-15 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
CA2958479A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
EP3204415B1
(en)
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
|
EP3215524B1
(en)
|
2014-11-06 |
2021-01-13 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
|
CN107074955B
(zh)
|
2014-11-20 |
2021-06-22 |
豪夫迈·罗氏有限公司 |
针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
|
EP3227338A4
(en)
|
2014-12-04 |
2018-05-16 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of acute myeloid leukemia
|
|
ES2744540T3
(es)
|
2014-12-05 |
2020-02-25 |
Hoffmann La Roche |
Anticuerpos anti-CD79b y procedimientos de uso
|
|
DK3233907T3
(da)
|
2014-12-19 |
2021-06-07 |
Genmab As |
Bispecifikke heterodimeriske proteiner hos gnavere
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
US11111314B2
(en)
|
2015-03-19 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
ES3012402T3
(en)
|
2015-04-13 |
2025-04-09 |
Pfizer |
Therapeutic antibodies and their uses
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック， インコーポレイテッド |
抗ｃｌｌ－１抗体及び使用方法
|
|
MY192978A
(en)
|
2015-06-22 |
2022-09-20 |
Janssen Biotech Inc |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
HUE066300T2
(hu)
|
2015-06-24 |
2024-07-28 |
Janssen Biotech Inc |
Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
EP3345928B1
(en)
|
2015-07-10 |
2020-06-24 |
Merus N.V. |
Human cd3 binding antibody
|
|
LT3319993T
(lt)
|
2015-07-10 |
2020-05-11 |
Genmab A/S |
Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
|
|
IL256562B2
(en)
|
2015-07-15 |
2024-07-01 |
Genmab As |
Human CD3 antibodies or chimeras
|
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
|
CA2994825A1
(en)
|
2015-08-05 |
2017-02-09 |
Janssen Biotech, Inc. |
Anti-cd154 antibodies and methods of using them
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
EP3356821B1
(en)
|
2015-10-02 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
|
EP3356417A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
PE20180773A1
(es)
|
2015-10-02 |
2018-05-07 |
Hoffmann La Roche |
Anticuerpos biespecificos para pd1 y tim3
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
IL258521B2
(en)
|
2015-10-08 |
2024-01-01 |
Macrogenics Inc |
Combination therapy for the treatment of cancer
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
BR112018008068A2
(en)
|
2015-10-23 |
2018-11-13 |
Merus N.V. |
binding molecules that inhibit cancer growth
|
|
CN114891102A
(zh)
|
2015-10-29 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
抗变体Fc区抗体及使用方法
|
|
PL3827845T3
(pl)
|
2015-11-03 |
2022-07-11 |
Janssen Biotech, Inc. |
Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
|
|
MX2018006333A
(es)
|
2015-12-01 |
2018-08-01 |
Genmab Bv |
Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
|
|
KR20180085800A
(ko)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
IL257696B2
(en)
|
2015-12-09 |
2024-11-01 |
Hoffmann La Roche |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
TW202208440A
(zh)
|
2015-12-14 |
2022-03-01 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
EP3390453A2
(en)
|
2015-12-17 |
2018-10-24 |
Janssen Biotech, Inc. |
Antibodies specifically binding hla-dr and their uses
|
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
DK3405490T3
(da)
|
2016-01-21 |
2022-01-10 |
Pfizer |
Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
|
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
|
|
FI3433280T3
(fi)
|
2016-03-22 |
2023-06-06 |
Hoffmann La Roche |
Proteaasin aktivoimia t-solubispesifisiä molekyylejä
|
|
MY198114A
(en)
|
2016-04-15 |
2023-08-04 |
Macrogenics Inc |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
JP7320943B2
(ja)
|
2016-04-28 |
2023-08-04 |
中外製薬株式会社 |
抗体含有製剤
|
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
コントースボディ−単鎖標的結合物質
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
UA128304C2
(uk)
|
2016-07-14 |
2024-06-05 |
Ґенмаб А/С |
Мультиспецифічне антитіло до cd40 і cd137
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
|
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
|
CN110214148A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
|
EP3535291A1
(en)
|
2016-11-01 |
2019-09-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
EP4653464A2
(en)
|
2016-12-23 |
2025-11-26 |
MacroGenics, Inc. |
Adam9-binding molecules, and methods of use thereof
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
KR20250140128A
(ko)
|
2017-02-10 |
2025-09-24 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
TW201834688A
(zh)
*
|
2017-02-24 |
2018-10-01 |
日商中外製藥股份有限公司 |
藥學組成物、抗原結合分子、治療方法以及篩選方法
|
|
BR112019017500A2
(pt)
|
2017-03-03 |
2020-04-14 |
Rinat Neuroscience Corp |
anticorpos anti-gitr e métodos de uso dos mesmos
|
|
CN116836285A
(zh)
|
2017-03-09 |
2023-10-03 |
健玛保 |
针对pd-l1的抗体
|
|
SG11201908127WA
(en)
|
2017-03-10 |
2019-10-30 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
|
EP3601354A1
(en)
|
2017-03-31 |
2020-02-05 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
CA3058343A1
(en)
|
2017-03-31 |
2018-10-04 |
Merus N.V. |
Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
|
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
BR112019018767A2
(pt)
|
2017-04-03 |
2020-05-05 |
Hoffmann La Roche |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
|
|
PT3606946T
(pt)
|
2017-04-03 |
2022-10-17 |
Hoffmann La Roche |
Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
|
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
US12195551B2
(en)
|
2017-05-17 |
2025-01-14 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
WO2018217947A1
(en)
*
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
|
CA3064660A1
(en)
*
|
2017-06-01 |
2018-12-06 |
Universitat Stuttgart |
Heterodimerizing ig domains
|
|
EP3630841A1
(en)
|
2017-06-02 |
2020-04-08 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
|
CN111328335A
(zh)
|
2017-06-07 |
2020-06-23 |
根马布私人有限公司 |
基于突变igg六聚体的治疗性抗体
|
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
JP7290013B2
(ja)
|
2017-08-04 |
2023-06-13 |
ジェンマブ エー／エス |
Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
|
|
HUE071182T2
(hu)
|
2017-08-09 |
2025-08-28 |
Merus Nv |
EGFR és CMET kötõ antitestek
|
|
CN111246885B
(zh)
|
2017-10-20 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
|
SG11202002903XA
(en)
|
2017-11-01 |
2020-04-29 |
Hoffmann La Roche |
Bispecific 2+1 contorsbodies
|
|
CN111295392A
(zh)
|
2017-11-01 |
2020-06-16 |
豪夫迈·罗氏有限公司 |
Compbody–多价靶结合物
|
|
AU2018361430B2
(en)
|
2017-11-01 |
2025-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody variant and isoform with lowered biological activity
|
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
|
JP7092881B2
(ja)
|
2017-11-01 |
2022-06-28 |
エフ．ホフマン－ラ ロシュ アーゲー |
ＴｒｉＦａｂコントースボディ
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021505637A
(ja)
|
2017-12-12 |
2021-02-18 |
マクロジェニクス，インコーポレーテッド |
二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
CN111527107B
(zh)
|
2017-12-21 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
结合hla-a2/wt1的抗体
|
|
CN111491951B
(zh)
|
2017-12-22 |
2024-05-24 |
豪夫迈·罗氏有限公司 |
通过疏水相互作用色谱法耗尽轻链错配的抗体变体
|
|
JP2021510740A
(ja)
|
2018-01-24 |
2021-04-30 |
ゲンマブ ビー．ブイ． |
ポリペプチド変種およびそれらの用途
|
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
|
PE20251579A1
(es)
|
2018-02-01 |
2025-06-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
|
MX2020007527A
(es)
|
2018-02-06 |
2020-09-09 |
Hoffmann La Roche |
Tratamiento de enfermedades oftalmologicas.
|
|
WO2019157340A1
(en)
*
|
2018-02-08 |
2019-08-15 |
Amgen Inc. |
Low ph pharmaceutical antibody formulation
|
|
CA3090236A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008289A
(es)
|
2018-02-08 |
2020-09-25 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso.
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP7466442B2
(ja)
|
2018-02-14 |
2024-04-12 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
AU2019222666B2
(en)
|
2018-02-15 |
2025-12-04 |
Macrogenics, Inc. |
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
|
|
KR102832460B1
(ko)
|
2018-02-20 |
2025-07-11 |
드래곤플라이 쎄라퓨틱스, 인크. |
Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
|
|
KR20240067985A
(ko)
|
2018-02-27 |
2024-05-17 |
화이자 인코포레이티드 |
항체 정제
|
|
EP3765493A2
(en)
|
2018-03-12 |
2021-01-20 |
Genmab A/S |
Antibodies
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
IL323061A
(en)
|
2018-04-11 |
2025-10-01 |
Inhibrx Biosciences Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
MX2020011552A
(es)
|
2018-05-03 |
2020-11-24 |
Genmab Bv |
Combinaciones de variantes de anticuerpos y usos de las mismas.
|
|
AU2019270624B2
(en)
|
2018-05-16 |
2024-05-02 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
|
|
DK3797121T3
(da)
|
2018-05-23 |
2024-07-08 |
Pfizer |
Antistoffer, der er specifikke for CD3, og anvendelser deraf
|
|
EP3810194A1
(en)
|
2018-06-22 |
2021-04-28 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
|
CA3106146A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Variants of cd38 antibody and uses thereof
|
|
US20240254252A1
(en)
|
2018-07-13 |
2024-08-01 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
|
CN112789294A
(zh)
|
2018-07-24 |
2021-05-11 |
印希比股份有限公司 |
含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
|
|
MA53293A
(fr)
|
2018-08-08 |
2021-11-17 |
Dragonfly Therapeutics Inc |
Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
MX2021001527A
(es)
|
2018-08-08 |
2021-06-15 |
Dragonfly Therapeutics Inc |
Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
|
|
JP7523349B2
(ja)
|
2018-08-29 |
2024-07-26 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
|
TW202506736A
(zh)
|
2018-10-11 |
2025-02-16 |
美商因荷布瑞克斯生物科學公司 |
5t4單域抗體及其治療性組合物
|
|
WO2020076970A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
US11208485B2
(en)
|
2018-10-11 |
2021-12-28 |
Inhibrx, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
CN120983617A
(zh)
|
2018-11-06 |
2025-11-21 |
健玛保 |
抗体配制剂
|
|
JP2022513708A
(ja)
|
2018-12-05 |
2022-02-09 |
モルフォシス・アーゲー |
多重特異性抗原結合分子
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
CA3123177A1
(en)
|
2018-12-21 |
2020-06-25 |
Kymab Limited |
Fixaxfx bispecific antibody with common light chain
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
TWI881476B
(zh)
|
2018-12-21 |
2025-04-21 |
瑞士商赫孚孟拉羅股份公司 |
結合cd3之抗體
|
|
SG11202106393SA
(en)
|
2018-12-24 |
2021-07-29 |
Sanofi Sa |
Pseudofab-based multispecific binding proteins
|
|
US20220073630A1
(en)
|
2018-12-28 |
2022-03-10 |
Hoffmann-La Roche, Inc. |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
PE20211977A1
(es)
|
2019-01-18 |
2021-10-05 |
Janssen Biotech Inc |
Receptores de antigenos quimericos de gprc5d y celulas que los expresan
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
CN113646622B
(zh)
|
2019-03-29 |
2024-11-12 |
豪夫迈·罗氏有限公司 |
用于多价分子的功能分析的基于spr的结合测定
|
|
CN113677701B
(zh)
|
2019-03-29 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
产生亲合结合多特异性抗体的方法
|
|
TW202106713A
(zh)
|
2019-04-25 |
2021-02-16 |
瑞士商赫孚孟拉羅股份公司 |
具延長半衰期之可活化治療性多特異性多肽
|
|
JP7688584B2
(ja)
|
2019-04-25 |
2025-06-04 |
エフ． ホフマン－ラ ロシュ アーゲー |
ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
|
|
JP2022531128A
(ja)
|
2019-04-25 |
2022-07-06 |
エフ．ホフマン－ラ ロシュ アーゲー |
ポリペプチド鎖交換による抗体由来ポリペプチドの生成
|
|
US20220315661A1
(en)
|
2019-05-09 |
2022-10-06 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
EP3969907B1
(en)
|
2019-05-13 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
|
TWI879770B
(zh)
*
|
2019-05-30 |
2025-04-11 |
美商安進公司 |
工程改造鉸鏈區以驅動抗體二聚化
|
|
CA3140297A1
(en)
|
2019-06-19 |
2020-12-24 |
Simon Auslaender |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
|
HUE071032T2
(hu)
|
2019-06-26 |
2025-07-28 |
Hoffmann La Roche |
Emlõs sejtvonalak SIRT-1 gén kiiktatásával
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
US12077585B2
(en)
|
2019-07-26 |
2024-09-03 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
PE20220394A1
(es)
|
2019-07-31 |
2022-03-18 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
|
PH12022550348A1
(en)
|
2019-08-15 |
2022-12-12 |
Janssen Biotech Inc |
Materials and methods for improved single chain variable fragments
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20220411529A1
(en)
|
2019-11-06 |
2022-12-29 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
MX2022005983A
(es)
|
2019-11-18 |
2022-09-07 |
Janssen Biotech Inc |
Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
|
|
BR112022011357A2
(pt)
|
2019-12-13 |
2022-08-23 |
Genentech Inc |
Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
|
|
PE20230160A1
(es)
|
2019-12-17 |
2023-02-01 |
Pfizer |
Anticuerpos especificos para cd47, pd-l1 y sus usos
|
|
EP4076663A1
(en)
|
2019-12-18 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Bispecific anti-ccl2 antibodies
|
|
PE20221282A1
(es)
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
|
CN113121697B
(zh)
*
|
2019-12-31 |
2023-06-09 |
周易 |
Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用
|
|
US11913945B2
(en)
|
2020-01-02 |
2024-02-27 |
Hoffmann-La Roche Inc. |
Method for determining the amount of a therapeutic antibody in the brain
|
|
PE20230113A1
(es)
|
2020-01-16 |
2023-01-27 |
Genmab As |
Formulaciones de anticuerpos anti-cd38 y usos de las mismas
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
IL295129A
(en)
|
2020-01-30 |
2022-09-01 |
Umoja Biopharma Inc |
Bispecific transduction enhancer
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
UY40280A
(es)
|
2020-03-13 |
2023-07-31 |
Janssen Biotech Inc |
Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides
|
|
AU2021236906A1
(en)
|
2020-03-18 |
2022-08-18 |
Genmab A/S |
Antibodies binding to B7H4
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
EP4135848A2
(en)
|
2020-04-15 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Immunoconjugates
|
|
JP2023524068A
(ja)
|
2020-04-30 |
2023-06-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
サイトカイン関連有害事象を治療する方法
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
US20230227570A1
(en)
|
2020-05-08 |
2023-07-20 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
EP4149524A1
(en)
|
2020-05-11 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
KR20230017841A
(ko)
|
2020-05-27 |
2023-02-06 |
얀센 바이오테크 인코포레이티드 |
Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
|
AR122657A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
WO2021255143A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and folr1
|
|
AU2021291407A1
(en)
|
2020-06-19 |
2022-09-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
|
EP4185388A1
(en)
|
2020-07-23 |
2023-05-31 |
Genmab B.V. |
A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
TW202221028A
(zh)
|
2020-07-29 |
2022-06-01 |
美商健生生物科技公司 |
包括hla-g抗原結合域之蛋白及其用途
|
|
AU2021322046A1
(en)
|
2020-08-06 |
2023-02-02 |
BioNTech SE |
Binding agents for coronavirus S protein
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
EP4208200A2
(en)
|
2020-09-02 |
2023-07-12 |
Genmab A/S |
Antibody therapy
|
|
JP2023541860A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
|
KR20230068415A
(ko)
|
2020-09-24 |
2023-05-17 |
에프. 호프만-라 로슈 아게 |
유전자 녹아웃을 갖는 포유류 세포주
|
|
CN116438198A
(zh)
|
2020-10-02 |
2023-07-14 |
健玛保 |
能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
|
|
UY39467A
(es)
|
2020-10-13 |
2022-04-29 |
Janssen Biotech Inc |
Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
|
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
|
|
TWI888665B
(zh)
|
2020-11-04 |
2025-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
|
US12351643B2
(en)
|
2020-11-04 |
2025-07-08 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
EP4245317A4
(en)
|
2020-11-10 |
2024-11-06 |
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. |
BISPECIFIC ANTIBODY FOR CLAUDIN 18A2 AND CD3 AND APPLICATION OF BISPECIFIC ANTIBODY
|
|
PE20240819A1
(es)
|
2020-12-17 |
2024-04-18 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
|
EP4263595A1
(en)
|
2020-12-18 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Precursor proteins and kit for targeted therapy
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
IL304067A
(en)
|
2021-01-06 |
2023-08-01 |
Hoffmann La Roche |
Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
US11639396B2
(en)
|
2021-02-16 |
2023-05-02 |
Janssen Biotech, Inc. |
Antibody binding to a linker peptide
|
|
EP4295154A1
(en)
|
2021-02-18 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Method for resolving complex, multistep antibody interactions
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
JP2024512386A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェンマブ エー／エス |
非活性化抗体バリアント
|
|
CN117098781A
(zh)
|
2021-03-24 |
2023-11-21 |
詹森生物科技公司 |
靶向cd22和cd79b的抗体
|
|
CA3214307A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
WO2022206872A1
(zh)
|
2021-03-31 |
2022-10-06 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
|
TW202244059A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
MX2023012408A
(es)
|
2021-04-30 |
2023-10-31 |
Hoffmann La Roche |
Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
|
|
JP2024519212A
(ja)
|
2021-05-07 |
2024-05-09 |
ジェンマブ エー／エス |
Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物
|
|
TW202306990A
(zh)
|
2021-05-12 |
2023-02-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途
|
|
CN117120478A
(zh)
|
2021-05-14 |
2023-11-24 |
江苏恒瑞医药股份有限公司 |
一种抗原结合分子
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
CA3221735A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
US20240262924A1
(en)
|
2021-06-21 |
2024-08-08 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
|
CA3225715A1
(en)
|
2021-07-14 |
2023-01-19 |
Xin Ye |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
|
CN117715939A
(zh)
|
2021-07-27 |
2024-03-15 |
莫佛塞斯公司 |
抗原结合分子的组合
|
|
MX2024001214A
(es)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Metodos y composiciones para tratar cancer.
|
|
KR20240051280A
(ko)
|
2021-09-06 |
2024-04-19 |
젠맵 에이/에스 |
Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
|
|
AU2022344595A1
(en)
|
2021-09-13 |
2024-05-02 |
Janssen Biotech, Inc |
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
|
|
CN117813323A
(zh)
|
2021-09-23 |
2024-04-02 |
江苏恒瑞医药股份有限公司 |
抗klb抗体及用途
|
|
US20250019455A1
(en)
|
2021-09-24 |
2025-01-16 |
Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
US20240400670A1
(en)
|
2021-09-30 |
2024-12-05 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-il23 antibody fusion protein and uses thereof
|
|
JP7503215B2
(ja)
|
2021-10-08 |
2024-06-19 |
ジェンマブ エー／エス |
Ｃｄ３０及びｃｄ３に結合する抗体
|
|
EP4416174A1
(en)
|
2021-10-14 |
2024-08-21 |
F. Hoffmann-La Roche AG |
New interleukin-7 immunoconjugates
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
AU2022369312A1
(en)
|
2021-10-20 |
2024-05-02 |
Synthekine, Inc. |
Heterodimeric fc cytokines and uses thereof
|
|
AU2022380722A1
(en)
|
2021-11-03 |
2024-06-20 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
CA3239224A1
(en)
|
2021-11-22 |
2023-05-25 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
EP4437344A1
(en)
|
2021-11-25 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Quantification of low amounts of antibody sideproducts
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
US20250043022A1
(en)
|
2022-02-07 |
2025-02-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
|
|
JP2025508692A
(ja)
|
2022-02-11 |
2025-04-10 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
免疫複合体及びその使用
|
|
CA3254037A1
(en)
|
2022-03-03 |
2023-09-07 |
Pfizer |
MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
CA3245807A1
(en)
|
2022-03-14 |
2025-06-13 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Antigen-binding molecule specifically binding to GPRC5D and CD3 and its medical use
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
KR20240164782A
(ko)
|
2022-03-23 |
2024-11-20 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
|
|
CA3247048A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech Inc |
PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE
|
|
KR20250004776A
(ko)
|
2022-04-13 |
2025-01-08 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
|
|
JP2025513335A
(ja)
|
2022-04-19 |
2025-04-24 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
IL316628A
(en)
|
2022-05-12 |
2024-12-01 |
Genmab As |
Binding agents capable of binding to CD27 in combination therapy
|
|
JP2025517572A
(ja)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
AU2023287212A1
(en)
|
2022-06-23 |
2024-12-19 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
|
|
MA71622A
(fr)
|
2022-07-29 |
2025-05-30 |
Alector Llc |
Domaines de liaison à l'antigène cd98hc et leurs utilisations
|
|
EP4562044A2
(en)
|
2022-07-29 |
2025-06-04 |
Alector LLC |
Transferrin receptor antigen-binding domains and uses therefor
|
|
IL318357A
(en)
|
2022-08-03 |
2025-03-01 |
Pfizer |
ANTI-IL27R antibodies and methods of using them
|
|
KR20250046283A
(ko)
|
2022-08-05 |
2025-04-02 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Gucy2c 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
KR20250096769A
(ko)
|
2022-11-01 |
2025-06-27 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
글리피칸-3에 대한 이중특이성 항체 및 이의 용도
|
|
AU2023375177A1
(en)
|
2022-11-02 |
2025-06-19 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4619427A1
(en)
|
2022-11-15 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Recombinant binding proteins with activatable effector domain
|
|
JP2025539760A
(ja)
|
2022-11-15 |
2025-12-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合分子
|
|
AU2023404602A1
(en)
|
2022-11-29 |
2025-05-29 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Cldn18.2/4-1bb binding protein and medical use thereof
|
|
CN120548192A
(zh)
|
2023-01-20 |
2025-08-26 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
TW202436339A
(zh)
|
2023-01-31 |
2024-09-16 |
瑞士商赫孚孟拉羅股份公司 |
治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
CN120835901A
(zh)
|
2023-03-13 |
2025-10-24 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
|
|
CN120917044A
(zh)
|
2023-04-03 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
激动性拆分型抗体
|
|
CN120882744A
(zh)
|
2023-04-03 |
2025-10-31 |
豪夫迈·罗氏有限公司 |
一体化激动性抗体
|
|
TW202506178A
(zh)
|
2023-04-05 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
|
|
TW202506702A
(zh)
|
2023-04-07 |
2025-02-16 |
美商輝瑞股份有限公司 |
自同源二聚體抗體形成多特異性抗體之方法和包括自該方法得到的多特異性抗體之醫藥產物
|
|
KR20250163373A
(ko)
|
2023-04-11 |
2025-11-20 |
바이오레이 파마슈티컬 씨오., 엘티디. |
항-ror1 항체 및 그 약물 접합체
|
|
AR132623A1
(es)
|
2023-05-08 |
2025-07-16 |
Hoffmann La Roche |
PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
|
|
AR132668A1
(es)
|
2023-05-12 |
2025-07-16 |
Genmab As |
Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos
|
|
AR132687A1
(es)
|
2023-05-16 |
2025-07-23 |
Hoffmann La Roche |
Inmunoconjugados de il-2 regulados por pd-1 y sus usos
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
TW202509077A
(zh)
|
2023-06-30 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
與纖維母細胞活化蛋白α及死亡受體４結合之抗體
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
AR133412A1
(es)
|
2023-07-30 |
2025-09-24 |
Janssen Biotech Inc |
Moléculas que se unen a la calreticulina mutante y usos de estas
|
|
WO2025034715A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Gucy2c antibodies and uses thereof
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025054328A1
(en)
|
2023-09-05 |
2025-03-13 |
Tizona Therapeutics |
Bispecific binding construct capable of binding to ackr4, compositions comprising a bispecific binding construct capable of binding to ackr4, and methods of using bispecific binding construct capable of binding to ackr4
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
WO2025088516A1
(en)
|
2023-10-26 |
2025-05-01 |
Pfizer Inc. |
Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained
|
|
WO2025101982A1
(en)
|
2023-11-10 |
2025-05-15 |
Pfizer Inc. |
Anti-migis-alpha antibodies and methods of use thereof
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025137454A1
(en)
*
|
2023-12-21 |
2025-06-26 |
Amgen Inc. |
Stabilizing homodimer mutations for two cell heterodimer production
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025231408A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|